Get to know our clinical trials

Clinical trial of Atezolizumab with Lenvatinib or Sorafenib in hepatocellular carcinoma previously treated with Atezolizumab and Bevacizumab.

THE AIM OF THIS STUDY IS TO COMPARE THE EFFECTS, GOOD OR BAD, OF ATEZOLIZUMAB COMBINED WITH ONE OF TWO ORAL DRUGS (LENVATINIB OR SORAFENIB) COMPARED TO RECEIVING ONLY ONE OF THESE ORAL DRUGS (LENVATINIB OR SORAFENIB) IN PEOPLE WITH HCC WHOSE DISEASE HAS PROGRESSED AFTER A FIRST LINE OF TREATMENT WITH ATEZOLIZUMAB PLUS BEVACIZUMAB.

Director Hepatology Unit
Navarre headquarters
Madrid headquarters
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB COMPARED TO LENVATINIB OR SORAFENIB MONOTHERAPY IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB. IMMUNOTHERAPY
  • Code EudraCT: 2020-005231-78
  • Protocol number: MO42541
  • Promoter: Roche Farma, S.A.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.